Skip to content

Press

Portfolio-Media Coverage
Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
July 15, 2024 Jul 15, 2024
Portfolio-Media Coverage
Cerevance and a new approach to Parkinson’s disease
June 11, 2024 Jun 11, 2024 Raising Biotech
Portfolio-Media Coverage
Intellia and Recode collaborate on genomic medicines for cystic fibrosis
February 16, 2024 Feb 16, 2024 BioWorld
Portfolio-Media Coverage
Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF
February 16, 2024 Feb 16, 2024 LabPulse
Portfolio-Media Coverage
Intellia, ReCode team up to develop gene-editing therapies for CF
February 16, 2024 Feb 16, 2024 Cystic Fibrosis News Today
Portfolio-Media Coverage
Intellia and ReCode join forces on cystic fibrosis gene therapy
February 15, 2024 Feb 15, 2024 Investing.com
Portfolio-Media Coverage
Intellia and ReCode Join Forces to Revolutionize Cystic Fibrosis Treatment with CRISPR Gene-Editing
February 15, 2024 Feb 15, 2024 BNN
Portfolio-Media Coverage
JPM24: ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity
January 17, 2024 Jan 17, 2024 Fierce Biotech
Portfolio-Media Coverage
The Therapeutic Areas that Stood Out in BioSpace’s NextGen Class of 2024
January 8, 2024 Jan 8, 2024 BioSpace
Portfolio-Media Coverage
ReCode doses first subject in Phase I primary ciliary dyskinesia trial
January 4, 2024 Jan 4, 2024 Clinical Trials Arena